Loading the records…
Byron Donalds
RepublicanFL19•house•Filed Jan 7, 2026
View all of Byron Donalds's trades →18 total filings on record
Byron Donalds (R-FL) sold $1K-$15K of $ABT (Abbott Laboratories Common Stock) on Dec 4, 2025, part of 5 transactions in this filing (3 buys, 2 sells).
Transactions
5
Companies
2
Largest Trade
$50K-$100K
Timing Flags
None
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Health Care
Infrastructure & Construction
🔒
Sign Up to See More
See the full trade breakdown, suspicious timing flags, and how this filing connects to active legislation.
Get Free Access →Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | Cryptocurrency | Bitcoin(Cryptocurrency) | $50K-$100K | — | — | — | Dec 18, 2025 |
| BUY | $FIX | Comfort Systems USA, Inc. Common Stock | $1K-$15K | $1,004.65 | — | — | Dec 4, 2025 |
| BUY | $FIX | Comfort Systems USA, Inc. Common Stock | $1K-$15K | $1,004.65 | — | — | Dec 4, 2025 |
| SELL | $ABT | Abbott Laboratories Common Stock | $1K-$15K | $125.40 | — | — | Dec 4, 2025 |
| SELL | $ABT | Abbott Laboratories Common Stock | $1K-$15K | $125.40 | — | — | Dec 4, 2025 |
BUY$50K-$100K
CryptocurrencyBitcoin
Dec 18, 2025 \u2022 self
Connected Legislative Activity
5 signalsThese bills and contracts share tickers or sectors with this filing's trades.
BillHR6897neutral
Thyroid Disease CARE Act of 2025
HR6897 (Thyroid Disease CARE Act) authorizes $30M/year for five years for thyroid disease research and improved diagnostics. The bill is in early stage — referred to House Energy and Commerce Committee on December 18, 2025. Real market data shows diagnostic stocks trending negative over the past 30 days, with Labcorp down 1.53% and Abbott down 11.85%. Any impact is procedural and speculative at this stage.
Dec 18, 2025
DGXLHTMO
BillHR7879neutral
To require the Secretary of State, in consultation with the Secretary of Health and Human Services and other relevant departments and agencies, as appropriate, to formulate a strategy for the Federal Government to secure support from foreign countries, multilateral organizations, and other appropriate entities to facilitate the development and commercialization of qualified pandemic or epidemic products, and for other purposes.
The SUPER BUGS Act (HR7879) is a procedural bill with zero funding, no procurement mechanism, and no regulatory impact. It requires the State Department to develop a strategy for international pandemic product collaboration. Market impact is negligible — recent price moves in $PFE (-1.41% 7d), $MRNA (-7.27% 7d), $JNJ (+1.01% 7d), and $GILD (+0.18% 7d) reflect broader sector trends, not this legislation.
Mar 9, 2026
JNJMRNAPFE
BillHR210bullish
Dental Care for Veterans Act
The Dental Care for Veterans Act (HR210) expands VA dental eligibility to all enrolled veterans, creating an estimated $5-10B annual procurement opportunity for dental suppliers. The bill has 95 cosponsors and passed committee hearings but no appropriations are authorized. HSIC and XRAY are the strongest structural beneficiaries given their pure-play dental exposure.
Mar 18, 2026
BillS3304bullish
Medical Foods and Formulas Access Act of 2025
S.3304 mandates federal health program coverage for medical foods, creating a new guaranteed payment stream for manufacturers. Abbott Laboratories ($ABT), the dominant U.S. player in metabolic formulas through its Nutrition division, is the primary beneficiary. The bill is early-stage (referred to Finance Committee) but has bipartisan sponsorship and an identical House companion, providing moderate legislative momentum.
Dec 2, 2025
ABT
BillHR7867bearish
To amend the Federal Food, Drug, and Cosmetic Act to establish standardized pathogen and microorganism testing of infant formula products and manufacturing facilities, to mandate notification of specific positive tests and inspection classifications, and for other purposes.
HR7867 (Infant Formula Safety Modernization Act) directly burdens Abbott Laboratories ($ABT) with new mandatory testing and notification requirements at a time when $ABT is trading at $90.35, just $0.02 above its 52-week low. The bill is early-stage (referred to committee) but represents an additional regulatory headwind for the dominant US infant formula manufacturer already under FDA scrutiny after the 2022 plant shutdown.
Mar 9, 2026
ABT
Other Filings by Byron Donalds
Free — no credit card
Get the next Donalds trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.